Tylenol Manufacturers Paying $33 Million in Settlement

Comments (0)

McNeil-PPC, which is the maker of Tylenol, has agreed to pay $33 million to settle allegations that the company distributed contaminated drugs and illegally promoted its products. The charges were brought by the Attorneys General of 43 states.

The company recalled hundreds of millions of packages of drugs it produced between 2009 and 2011. Many of those drugs were for use in infants and children. At the time of the recalls, there were reports of odd problems with the products, such as weird odors and particles found in liquid medicines. The recalled products included Tylenol, Zyrtec, Rolaids, Motrin, Benadryl, Sudafed, Pepcid, Mylanta, and St. Joseph Aspirin.

After the recalls, several states began investigating the practices of the drug company, and alleged that its over-the-counter medications were not compliant with good manufacturing practices, although the company claimed they were. The tainted medications appear to have come from one facility that was not following federal law.  

The U.S. Department of Justice also opened an investigation which resulted in a misdemeanor guilty plea, and a criminal fine of $20 million and a forfeiture of $5 million. The settlement that was just reached with the states restricts the company’s advertising, and adds requirements that must be met by the company to safeguard consumers. If there is a recall in the future, the company must notify the Attorneys General regarding the identity of wholesalers and warehouses where the drugs that are subject to the recall were distributed.

This is not an uncommon story. Many drug manufacturers become more concerned with their profits than protecting their customers. Fortunately, the legal system offers compensation to individuals who have been harmed by the wrongful actions of drug companies. If you have been harmed by a prescription or over-the-counter drug, call the Houston defective drug attorneys at Kennedy Hodges at 855-947-0707. They can help. Call today to learn more or visit us on Twitter.

Be the first to comment!

Post a Comment

To reply to this message, enter your reply in the box labeled "Message", hit "Post Message."


Email:* (will not be published)


Notify me of follow-up comments via email.